Evaluating the Safety of Maribavir for the Treatment of Cytomegalovirus
- PMID: 35308097
- PMCID: PMC8926008
- DOI: 10.2147/TCRM.S303052
Evaluating the Safety of Maribavir for the Treatment of Cytomegalovirus
Abstract
Purpose of review: Cytomegalovirus (CMV) infections are a common complication in solid organ (SOT) and hematopoietic stem cell transplant (HSCT) recipients, leading to increased morbidity and mortality. Currently available treatment options have reduced the burden of infection, but utilization of these agents can be limited by toxicities such as nephrotoxicity and/or myelosuppression as well as emergence of resistance. The expansion of our current armamentarium towards CMV infection is crucial. Here, we review an emerging therapy, maribavir, and the safety and efficacy of this potential new agent for the prophylaxis and treatment of CMV infections including resistant/refractory disease.
Recent findings: Maribavir is a novel agent with CMV activity approved by Federal Food and Drug Administration (FDA) in December 2021 for resistant/refractory disease. Compared to currently available treatment for CMV infection, maribavir has a unique mechanism of action, retains activity against most (val)ganciclovir resistant strains, provides a more predictable pharmacokinetic profile, and fewer severe toxicities. Maribavir has been studied in phase 2 and 3 studies with ongoing phase 3 studies. While maribavir failed to meet the primary endpoints in the initial phase 3 study for prophylaxis therapy in allogeneic-HSCT and liver transplant recipients, results from the phase 2 study when used for pre-emptive therapy after HSCT show similar efficacy to valganciclovir, and results from the phase 3 study examining resistant/refractory disease demonstrate superiority to investigator-initiated therapy of (val)ganciclovir, foscarnet, or cidofovir.
Summary: Maribavir provides a new agent for the management of resistant/refractory CMV infection. Results of the recently published phase 3 study provide further insight into the role of this novel therapy.
Keywords: cytomegalovirus; efficacy; maribavir; safety.
© 2022 Gandhi and Kotton.
Conflict of interest statement
Ronak G. Gandhi has been a paid consultant to Takeda and Shionogi. Camille N. Kotton has been a paid consultant to Biotest, GSK, Merck, Takeda, Roche Diagnostics, and Hookipa. The authors report no other conflicts of interest in this work.
Similar articles
-
New Perspectives on Antimicrobial Agents: Maribavir.Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0240521. doi: 10.1128/aac.02405-21. Epub 2022 Aug 2. Antimicrob Agents Chemother. 2022. PMID: 35916518 Free PMC article. Review.
-
Current Perspectives on Letermovir and Maribavir for the Management of Cytomegalovirus Infection in Solid Organ Transplant Recipients.Drug Des Devel Ther. 2024 Sep 6;18:3987-4001. doi: 10.2147/DDDT.S265644. eCollection 2024. Drug Des Devel Ther. 2024. PMID: 39258274 Free PMC article. Review.
-
Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study.Clin Infect Dis. 2019 Apr 8;68(8):1255-1264. doi: 10.1093/cid/ciy706. Clin Infect Dis. 2019. PMID: 30329038 Free PMC article. Clinical Trial.
-
Maribavir for the Management of Cytomegalovirus in Adult Transplant Recipients: A Review of the Literature and Practical Considerations.Ann Pharmacother. 2023 May;57(5):597-608. doi: 10.1177/10600280221118959. Epub 2022 Aug 24. Ann Pharmacother. 2023. PMID: 36003036 Review.
-
Management of Cytomegalovirus Infections in the Era of the Novel Antiviral Players, Letermovir and Maribavir.Infect Dis Rep. 2024 Jan 18;16(1):65-82. doi: 10.3390/idr16010005. Infect Dis Rep. 2024. PMID: 38247977 Free PMC article. Review.
Cited by
-
Bring it on again: antimicrobial stewardship in transplant infectious diseases: updates and new challenges.Antimicrob Steward Healthc Epidemiol. 2024 Jan 11;4(1):e3. doi: 10.1017/ash.2023.517. eCollection 2024. Antimicrob Steward Healthc Epidemiol. 2024. PMID: 38234416 Free PMC article. Review.
-
The 'Oma's of the Gammas-Cancerogenesis by γ-Herpesviruses.Viruses. 2024 Dec 17;16(12):1928. doi: 10.3390/v16121928. Viruses. 2024. PMID: 39772235 Free PMC article. Review.
-
Real-world safety of maribavir: a retrospective study based on signal detection in the FDA adverse event reporting system.Int J Clin Pharm. 2025 Jun;47(3):767-774. doi: 10.1007/s11096-025-01869-4. Epub 2025 Jan 17. Int J Clin Pharm. 2025. PMID: 39821007
-
Letermovir Rescue Therapy in Kidney Transplant Recipients with Refractory/Resistant CMV Disease.J Clin Med. 2023 Dec 23;13(1):100. doi: 10.3390/jcm13010100. J Clin Med. 2023. PMID: 38202107 Free PMC article.
-
Current Perspectives on the Management of Herpesvirus Infections in Solid Organ Transplant Recipients.Viruses. 2023 Jul 21;15(7):1595. doi: 10.3390/v15071595. Viruses. 2023. PMID: 37515280 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources
Research Materials